Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities

ACS Chemical Biology

Volumn 9, Issue 3, 2014, Pages 802-811

  Huang, Yijun ^a   Wolf, Siglinde ^b   Beck, Barbara ^c,d   Köhler, Lisa Maria ^c   Khoury, Kareem ^a   Popowicz, Grzegorz M ^b   Goda, Sayed K ^e   Subklewe, Marion ^c,d   Twarda, Aleksandra ^f   Holak, Tad A ^b,f   Dömling, Alexander ^a,g  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Anti Doping Lab Qatar   (Qatar)

^f JAGIELLONIAN UNIVERSITY   (Poland)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 7; NUTLIN 3; PRODRUG; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; YH 239 EE; ANTINEOPLASTIC AGENT; ETHYL 3-(2-((TERT-BUTYLAMINO)-1-(N-(4-CHLOROBENZYL)FORMAMIDO)-2-OXOETHYL)-6-CHLORO-1H-INDOLE-2-CARBOXYLATE; INDOLE DERIVATIVE; PROTEIN BINDING;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; WILD TYPE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DRUG DISCOVERY; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896930690     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400728e     Document Type: Article

References (35)

1. Wang, S., Zhao, Y., Bernard, D., Aguilar, A., and Kumar, S. (2009) Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics, in Protein-Protein Interactions (Wendt, M. D., Ed.) Vol. 8, pp 57-79, Springer, Berlin, Heidelberg.
2. Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A., and Albitar, M. (1993) The human MDM-2 oncogene is overexpressed in leukemias Blood 82, 2617-2623
3. Joerger, A. C. and Fersht, A. R. (2008) Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 77, 557-582
4. Joerger, A. C. and Fersht, A. R. (2010) The tumor suppressor p53: from structures to drug discovery Cold Spring Harb. Perspect. Biol 2, a000919
5. Secchiero, P., Zerbinati, C., Melloni, E., Milani, D., Campioni, D., Fadda, R., Tiribelli, M., and Zauli, G. (2007) The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts Neoplasia 9, 853-861
6. Long, J., Parkin, B., Ouillette, P., Bixby, D., Shedden, K., Erba, H., Wang, S., and Malek, S. N. (2010) Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia Blood 116, 71-80
7. Beryozkina, A., Nichols, G. L., Reckner, M., Vassilev, L. T., Rueger, R., Jukofsky, L., Middleton, S., Andreeff, M., Padmanabhan, S., Strair, R., Delioukina, M. L., Maslak, P. G., Hillmen, P., Kurzrock, R., Gore, L., Patnaik, A., Maki, R. G., Schwartz, G. K., Wagner, A. J., and Zhi, J. (2011) Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors J. Clin. Oncol. 29 (15-suppl, ASCO Annual Meeting Abstracts) 3039
8. Huang, Y., Wolf, S., Koes, D., Popowicz, G. M., Camacho, C. J., Holak, T. A., and Dömling, A. (2012) Exhaustive fluorine scanning toward potent p53-MDM2 antagonists ChemMedChem 7, 49-52
9. Koes, D., Khoury, K., Huang, Y., Wang, W., Bista, M., Popowicz, G. M., Wolf, S., Holak, T. A., Dömling, A., and Camacho, C. J. (2012) Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists PLoS One 7, e32839
10. Dömling, A. and Ugi, I. (2000) Multicomponent reactions with isocyanides Angew. Chem., Int. Ed. 39, 3169-3210
11. Czarna, A., Beck, B., Srivastava, S., Popowicz, G. M., Wolf, S., Huang, Y., Bista, M., Holak, T. A., and Dömling, A. (2010) Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/HDM2 antagonists Angew. Chem., Int. Ed. 49, 5352-5356
12. Picksley, S. M., Vojtesek, B., Sparks, A., and Lane, D. P. (1994) Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding-site on p53 using synthetic peptides Oncogene 9, 2523-2529
13. Popowicz, G. M., Dömling, A., and Holak, T. A. (2011) The structure-based design of MDM2/MDMX-p53 inhibitors gets serious Angew. Chem., Int. Ed. 50, 2680-2688
14. Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A., and Holak, T. A. (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 9, 1104-1111
15. Srivastava, S., Beck, B., Wang, W., Czarna, A., Holak, T. A., and Dömling, A. (2009) Rapid and efficient hydrophilicity tuning of p53/MDM2 antagonists J. Comb. Chem. 11, 631-639
16. Huang, Y., Wolf, S., Bista, M., Meireles, L., Camacho, C., Holak, T. A., and Dömling, A. (2010) 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-MDM2 activity Chem. Biol. Drug Design 76, 116-129
17. Dömling, A. and Huang, Y. J. (2010) Piperazine scaffolds via isocyanide-based multicomponent reactions Synthesis 17, 2859-2883
18. Ribelin, T. P., Judd, A. S., Akritopoulou-Zanze, I., Henry, R. F., Cross, J. L., Whittern, D. N., and Djuric, S. W. (2007) Concise construction of novel bridged bicyclic lactams by sequenced Ugi/RCM/Heck reactions Org. Lett. 9, 5119-5122
19. Wang, W., Herdtweck, E., and Dömling, A. (2010) Polycyclic indole alkaloid-type compounds by MCR Chem. Commun. 46, 770-772
20. Czarna, A., Popowicz, G. M., Pecak, A., Wolf, S., Dubin, G., and Holak, T. A. (2009) High affinity interaction of the p53 peptide-analogue with human MDM2 and MDMX Cell Cycle 8, 1176-1184
21. Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR Science 274, 1531-1534
22. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., Schumacher, R., Hesse, F., Kaluza, B., Voelter, W., Engh, R. A., and Holak, T. A. (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 Biochemistry 40, 336-344
23. Krajewski, M., Rothweiler, U., D'silva, L., Majumdar, S., Klein, C., and Holak, T. A. (2007) An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments J. Med. Chem. 50, 4382-4387
24. Bista, M., Kowalska, K., Janczyk, W., Dömling, A., and Holak, T. A. (2009) Robust NMR screening for lead compounds using tryptophan-containing proteins J. Am. Chem. Soc. 131, 7500-7501
25. Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A., and Holak, T. A. (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 9, 1104-1111
26. Wüthrich, K. (1986) NMR of Proteins and Nucleic Acids, Wiley, New York.
27. Rehm, T., Huber, R., and Holak, T. A. (2002) Application of NMR in structural proteomics: screening for proteins amenable to structural analysis Structure 10, 1613-1618
28. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 274, 948-953
29. Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., Maguire, D., Lattanze, J., Franks, C. F., Zhao, S., Ramachandren, K., Bylebyl, G. R., Zhang, M., Manthey, C. L., Petrella, E. C., Pantoliano, M. W., Deckman, I. C., Spurlino, J. C., Maroney, A. C., Tomczuk, B. E., Molloy, C. J., and Bone, R. F. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J. Med. Chem. 48, 909-912
30. Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., Matison, M. E., Schneider, S., Huang, X., Yu, D., Andrews, P. S., Reichelt, A., Long, A. M., Yakowec, P., Yang, E. Y., Lee, T. A., and Oliner, J. D. (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 52, 7044-7053
31. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303, 844-848
32. Matsuo, Y., MacLeod, R. A., Uphoff, C. C., Drexler, H. G., Nishizaki, C., Katayama, Y., Kimura, G., Fujii, N., Omoto, E., Harada, M., and Orita, K. (1997) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) Leukemia 11, 1469-1477
33. Wolf, D. and Rotter, V. (1985) Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells Proc. Natl. Acad. Sci. U.S.A. 82, 790-794
34. Fleckenstein, D. S., Uphoff, C. C., Drexler, H. G., and Quentmeier, H. (2002) Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines Leuk. Res. 26, 207-214
35. Van Gosliga, D., Schepers, H., Rizo, A., Van der Kolk, D., Vellenga, E., and Schuringa, J. J. (2007) Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells Exp. Hematol. 35, 1538